Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

Protein tyrosine kinases (PTKs) are a class of proteins with tyrosine kinase activity that
phosphorylate tyrosine residues of critical molecules in signaling pathways. Their basal …

Tumor drug resistance emerges from the interaction of two critical factors: tumor cellular
heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME) …

A strong relationship exists between tumor and inflammation, which is the hot point in cancer
research. Inflammation can promote the occurrence and development of cancer by …

Chronic liver injury with any etiology can progress to fibrosis and the end-stage diseases
cirrhosis and hepatocellular carcinoma. The progression of liver disease is controlled by a …

This study investigated the therapeutic effects of the phytochemical crocin alone or in
combination with sorafenib both in rats chemically induced with hepatocellular carcinoma …

The poor outcome of patients with non-surgically removable advanced hepatocellular
carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high …

Simple Summary There is no doubt that the need for new effective methods of cancer
treatment remains challenging, as cancer is the second cause of death based on the …

Hepatocellular carcinoma (HCC) has high mortality. The option of systemic therapy has
increased significantly over the past five years. Sorafenib was the first multikinase inhibitor …

Liver cancer is highly malignant and insensitive to cytotoxic chemotherapy and is associated
with very poor patient prognosis. In 2007, the small-molecule targeted drug sorafenib was …